X0607 3 2026-05-04 0 0001124105 GYRE THERAPEUTICS, INC. GYRE 0002061391 Xiong Yue false C/O GYRE THERAPEUTICS, INC. 12730 HIGH BLUFF DRIVE, SUITE 250 SAN DIEGO CA 92130 true Chief Scientific Officer Series B Preferred Stock Common Stock 2376500 D Following Stockholder Approval, each share of Series B Preferred Stock will be convertible, at the option of the holder, into five shares of common stock, subject to certain limitations, including the Beneficial Ownership Limitation (as such terms are defined in the Certificate of Designation for Series B Preferred Stock filed with the Securities and Exchange Commission as Exhibit 3.1 to the Issuer's Form 8-K filed on March 2, 2026). Effective as of May 4, 2026 (the "Effective Time"), a wholly-owned subsidiary of the Issuer merged with and into Cullgen Inc. ("Cullgen") with Cullgen surviving as a wholly-owned subsidiary of the Issuer (the "Merger"). Represents the number of shares of Series B Preferred Stock of the Issuer received by the Reporting Person in the Merger in exchange for the shares of capital stock of Cullgen held by the Reporting Person prior to the Merger. Each share of capital stock of Cullgen held at the Effective Time was exchanged for 0.4753 divided by five shares of Series B Preferred Stock. The Series B Preferred Stock has no expiration date. Exhibit 24 - Power of Attorney /s/ Thomas Eastling, as attorney-in-fact for Yue Xiong 2026-05-07